S&P keeps Grifols at 'B+', sees leverage decreasing in 2024
Ratings agency S&P on Friday kept its 'B+' rating for Grifols, with a stable outlook for 2024, in a boost for the Spanish pharmaceutical company after a report by short-seller Gotham City Research...